Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 3
2015 3
2016 3
2017 3
2018 6
2019 5
2020 6
2021 5
2022 8
2023 4
2024 4
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Results by year

Filters applied: . Clear all
Page 1
Napsin A-specific T-cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.
Miller NJ, Baik C, Neal JW, Sun F, Santana-Davila R, Lee S, Eaton KD, Martins RG, Rodriguez C, Wakelee H, Padda SK, Sotillo E, Konnick EQ, Camai A, Pisarenko T, Nair VS, Mackall C, Houghton AM, Chiou SH, Tseng D. Miller NJ, et al. Among authors: martins rg, rodriguez c. J Immunother Cancer. 2025 Jul 15;13(7):e011907. doi: 10.1136/jitc-2025-011907. J Immunother Cancer. 2025. PMID: 40664448 Free PMC article.
METHODS: Patients with metastatic non-small cell lung cancer (NSCLC) receiving anti-programmed cell death protein 1 (PD-1) and/or programmed death-ligand 1 (PD-L1) were enrolled at Fred Hutchinson Cancer Center and Stanford University Med …
METHODS: Patients with metastatic non-small cell lung cancer (NSCLC) receiving anti-programmed cell death protei …
Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.
Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, Chernock R, Tahara M, Harrington KJ, Klochikhin AL, Braña I, Vasconcelos Alves G, Hughes BGM, Oliva M, Pinto Figueiredo Lima I, Ueda T, Rutkowski T, Schroeder U, Mauz PS, Fuereder T, Laban S, Oridate N, Popovtzer A, Mach N, Korobko Y, Costa DA, Hooda-Nehra A, Rodriguez CP, Bell RB, Manschot C, Benjamin K, Gumuscu B, Adkins D; KEYNOTE-689 Investigators. Uppaluri R, et al. Among authors: rodriguez cp. N Engl J Med. 2025 Jul 3;393(1):37-50. doi: 10.1056/NEJMoa2415434. Epub 2025 Jun 18. N Engl J Med. 2025. PMID: 40532178 Clinical Trial.
BACKGROUND: The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear. METHODS: In this phase 3, open …
BACKGROUND: The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with …
Dual PD-1 and CTLA4 Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Advanced Salivary Gland Cancers.
Rodriguez CP, Wu QV, Ng K, Voutsinas J, Fromm JR, Dumenigo-Jimenez A, Martins RG, Eaton KD, Santana-Davila R, Baik C, Lee SM, Tseng D, Futran N, Barber B, Marchiano E, Laramore G, Lo SS, Liao JJ, Parvathaneni U. Rodriguez CP, et al. Among authors: martins rg. Head Neck. 2025 Apr 24. doi: 10.1002/hed.28169. Online ahead of print. Head Neck. 2025. PMID: 40275643
Among 19 response-evaluable patients, RECIST 1.1 PRs were observed in 4 (21%), in 2 pts. with salivary duct, 1 acinic cell, and 1 adenoid cystic, SD in 6 (31.5%) and PD in 9 (47.5%). With a median follow-up of 16 months, median OS was 25 months (95% CI: [18.7, 31]) and med …
Among 19 response-evaluable patients, RECIST 1.1 PRs were observed in 4 (21%), in 2 pts. with salivary duct, 1 acinic cell, and 1 ade …
Napsin A-specific T cell clonotypes are associated with improved clinical outcomes in patients receiving checkpoint immunotherapy for metastatic non-small cell lung cancer.
Miller NJ, Baik CS, Neal JW, Sun F, Santana-Davila R, Lee S, Eaton KD, Martins RG, Rodriguez C, Wakelee HA, Padda SK, Konnick EQ, Camai A, Pisarenko T, Nair VS, Houghton AM, Chiou SH, Tseng D. Miller NJ, et al. Among authors: martins rg, rodriguez c. medRxiv [Preprint]. 2025 Mar 13:2025.03.10.25323586. doi: 10.1101/2025.03.10.25323586. medRxiv. 2025. PMID: 40162291 Free PMC article. Preprint.
METHODS: Patients with metastatic non-small cell lung cancer (NSCLC) receiving anti-PD-(L)1 (alone or in combination) were enrolled at Fred Hutchinson Cancer Center and Stanford University Medical Center (n=62; histology of adenocarcinoma n=48, …
METHODS: Patients with metastatic non-small cell lung cancer (NSCLC) receiving anti-PD-(L)1 (alone or in combination) w …
NCCN Guidelines Insights: Head and Neck Cancers, Version 2.2025.
Colevas AD, Cmelak AJ, Pfister DG, Spencer S, Adkins D, Birkeland AC, Brizel DM, Busse PM, Caudell JJ, Durm G, Fakhry C, Galloway T, Geiger JL, Gillison ML, Glastonbury C, Haddad RI, Hicks WL, Hitchcock YJ, Jimeno A, Juloori A, Kase M, Leizman D, Maghami E, Mell LK, Mittal BB, Pinto HA, Price K, Rocco JW, Rodriguez CP, Schwartz D, Shah JP, Sher D, John MS, Wang H, Weinstein G, Worden F, Bruce JY, Yom SS, Zhen W, Montgomery S, Darlow SD. Colevas AD, et al. Among authors: rodriguez cp. J Natl Compr Canc Netw. 2025 Feb;23(2):2-11. doi: 10.6004/jnccn.2025.0007. J Natl Compr Canc Netw. 2025. PMID: 39938471
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharynx, larynx, and paranasal sinuses, as well as occult primary cancer, salivary gland cancer, and mucosal melanoma (MM). The specific site of d …
The NCCN Guidelines for Head and Neck Cancers address tumors arising in the oral cavity (including mucosal lip), pharyn …
Adjuvant Proton Beam Radiation Therapy for Sinonasal Mucosal Melanoma.
Takayesu JSK, Parvathaneni U, Laramore GE, Panjwani N, Sillings J, Futran ND, Humphreys IM, Jafari A, Abuzeid WM, Barber B, Marchiano E, Lee SM, Thompson JA, Hall E, Bhatia S, Rodriguez CP, Liao JJ. Takayesu JSK, et al. Among authors: rodriguez cp. Cancer Rep (Hoboken). 2025 Feb;8(2):e70111. doi: 10.1002/cnr2.70111. Cancer Rep (Hoboken). 2025. PMID: 39907094 Free PMC article.
BACKGROUND: Head and neck mucosal melanoma (HNMM) is rare and carries a poor prognosis with high rates of disease progression. ...
BACKGROUND: Head and neck mucosal melanoma (HNMM) is rare and carries a poor prognosis with high rates of disease progr …
Radiotherapy with cetuximab or durvalumab for locoregionally advanced head and neck cancer in patients with a contraindication to cisplatin (NRG-HN004): an open-label, multicentre, parallel-group, randomised, phase 2/3 trial.
Mell LK, Torres-Saavedra PA, Wong SJ, Kish JA, Chang SS, Jordan RC, Liu T, Truong MT, Winquist EW, Takiar V, Wise-Draper T, Robbins JR, Rodriguez CP, Awan MJ, Beadle BM, Henson C, Narayan S, Spencer SA, Powell S, Dunlap N, Sacco AG, Hu KS, Park HS, Bauman JE, Harris J, Yom SS, Le QT. Mell LK, et al. Among authors: rodriguez cp. Lancet Oncol. 2024 Dec;25(12):1576-1588. doi: 10.1016/S1470-2045(24)00507-2. Epub 2024 Nov 14. Lancet Oncol. 2024. PMID: 39551064 Free PMC article. Clinical Trial.
BACKGROUND: Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HNSCC) when cisplatin is contraindicated is controversial. ...Eligible patients were aged 18 years or older with American Joint Committee on C …
BACKGROUND: Management of patients with locoregionally advanced head and neck squamous cell carcinoma (HN …
Development of a prognostic signature for overall survival using peripheral blood biomarkers in head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
Pan C, Ng K, Voutsinas J, Barber B, Rizvi ZH, Marchiano E, Ferrandino RM, Futran N, Laramore GE, Liao JJ, Parvathaneni U, Panjwani N, Martins RG, Rodriguez CP, Wu QV. Pan C, et al. Among authors: martins rg, rodriguez cp. BMC Cancer. 2024 Nov 15;24(1):1406. doi: 10.1186/s12885-024-13051-6. BMC Cancer. 2024. PMID: 39543541 Free PMC article.
BACKGROUND: We previously reported in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with immune checkpoint inhibitors (ICIs), pretreatment higher lactate dehydrogenase (LDH) and absolute (abx) neutrophils as well …
BACKGROUND: We previously reported in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNS …
Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer.
Sarrett SM, Rodriguez C, Delaney S, Hosny MM, Sebastiano J, Santos-Coquillat A, Keinänen OM, Carter LM, Lastwika KJ, Lampe PD, Zeglis BM. Sarrett SM, et al. Among authors: rodriguez c. Mol Pharm. 2024 Mar 4;21(3):1402-1413. doi: 10.1021/acs.molpharmaceut.3c01063. Epub 2024 Feb 8. Mol Pharm. 2024. PMID: 38331430 Free PMC article.
Despite decades of work, small-cell lung cancer (SCLC) remains a frustratingly recalcitrant disease. Both diagnosis and treatment are challenges: low-dose computed tomography (the approved method used for lung cancer screening) is unable to reli …
Despite decades of work, small-cell lung cancer (SCLC) remains a frustratingly recalcitrant disease. Both diagnosis and …
PRT543, a protein arginine methyltransferase 5 inhibitor, in patients with advanced adenoid cystic carcinoma: An open-label, phase I dose-expansion study.
Ferrarotto R, Swiecicki PL, Zandberg DP, Baiocchi RA, Wesolowski R, Rodriguez CP, McKean M, Kang H, Monga V, Nath R, Palmisiano N, Babbar N, Sun W, Hanna GJ. Ferrarotto R, et al. Among authors: rodriguez cp. Oral Oncol. 2024 Feb;149:106634. doi: 10.1016/j.oraloncology.2023.106634. Epub 2023 Dec 20. Oral Oncol. 2024. PMID: 38118249 Free article. Clinical Trial.
46 results